NO940661L - Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus - Google Patents

Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus

Info

Publication number
NO940661L
NO940661L NO940661A NO940661A NO940661L NO 940661 L NO940661 L NO 940661L NO 940661 A NO940661 A NO 940661A NO 940661 A NO940661 A NO 940661A NO 940661 L NO940661 L NO 940661L
Authority
NO
Norway
Prior art keywords
peptides
hepatitis
hbv
virus
vaccines
Prior art date
Application number
NO940661A
Other languages
English (en)
Norwegian (no)
Other versions
NO940661D0 (no
Inventor
Francis V Chisari
Carlo Ferrari
Amalia Penna
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO940661D0 publication Critical patent/NO940661D0/no
Publication of NO940661L publication Critical patent/NO940661L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO940661A 1991-08-26 1994-02-25 Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus NO940661L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74954091A 1991-08-26 1991-08-26
PCT/US1992/007213 WO1993003753A1 (en) 1991-08-26 1992-08-26 Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus

Publications (2)

Publication Number Publication Date
NO940661D0 NO940661D0 (no) 1994-02-25
NO940661L true NO940661L (no) 1994-04-19

Family

ID=25014174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940661A NO940661L (no) 1991-08-26 1994-02-25 Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus

Country Status (19)

Country Link
EP (1) EP0534618B1 (de)
JP (3) JP3566284B2 (de)
AT (1) ATE320444T1 (de)
AU (1) AU679901B2 (de)
BG (1) BG98522A (de)
CA (1) CA2115927C (de)
CZ (1) CZ42894A3 (de)
DE (1) DE69233607T2 (de)
DK (1) DK0534618T3 (de)
ES (1) ES2262132T3 (de)
FI (1) FI940919L (de)
HU (1) HUT67529A (de)
IL (1) IL102963A0 (de)
NO (1) NO940661L (de)
NZ (2) NZ244102A (de)
OA (1) OA09889A (de)
PT (1) PT534618E (de)
WO (1) WO1993003753A1 (de)
ZA (1) ZA926440B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
CA2168583C (en) * 1993-08-02 2007-10-02 Francis V. Chisari Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
DE69820486D1 (de) * 1998-01-19 2004-01-22 Mogam Biotechnology Res Inst Y Liposomen, enthaltend peptidantigene, welche vom x-protein aus hepatitis b virus abstammen
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
GB0328753D0 (en) * 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
CA2955604A1 (en) * 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
WO2020145901A1 (en) * 2019-01-11 2020-07-16 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939900A (de) * 1972-08-25 1974-04-13
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9016727D0 (en) * 1990-07-31 1990-09-12 Clonit Spa Amino acid residue sequence of hepatitis b core antigen

Also Published As

Publication number Publication date
DE69233607D1 (de) 2006-05-11
IL102963A0 (en) 1993-01-31
BG98522A (bg) 1995-05-31
FI940919A7 (fi) 1994-04-25
NO940661D0 (no) 1994-02-25
PT534618E (pt) 2006-08-31
OA09889A (en) 1994-09-15
EP0534618A3 (en) 1993-06-30
CA2115927A1 (en) 1993-03-04
AU679901B2 (en) 1997-07-17
HUT67529A (en) 1995-04-28
DK0534618T3 (da) 2006-07-24
JP3694299B2 (ja) 2005-09-14
JP2003267997A (ja) 2003-09-25
CA2115927C (en) 2009-04-21
JP3694300B2 (ja) 2005-09-14
JP3566284B2 (ja) 2004-09-15
EP0534618B1 (de) 2006-03-15
JPH06510050A (ja) 1994-11-10
NZ270625A (en) 1996-12-20
JP2003300999A (ja) 2003-10-21
AU2540892A (en) 1993-03-16
FI940919A0 (fi) 1994-02-25
FI940919L (fi) 1994-04-25
ZA926440B (en) 1993-06-07
ES2262132T3 (es) 2006-11-16
DE69233607T2 (de) 2006-11-30
EP0534618A2 (de) 1993-03-31
WO1993003753A1 (en) 1993-03-04
NZ244102A (en) 1996-12-20
CZ42894A3 (en) 1995-02-15
HU9400582D0 (en) 1994-07-28
ATE320444T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
EP1018344A3 (de) HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
EP0726758A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
Jung et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers
Wiktor Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
DE60142562D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
Rafiq et al. Hazards of hepatitis at the Hajj
Pinto et al. Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses
Tuncer et al. Vaccination in individuals with multiple sclerosis–part II
Emir et al. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer
RU94038427A (ru) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
Piri Çınar et al. Vaccination in Individuals with Multiple Sclerosis–Part II Multipl Skleroz Tanılı Bireylerde Aşılama–Bölüm II
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
Kalayanarooj et al. Protective antibody after a'one dollar'hepatitis B vaccine
Cossart Influenza haemagglutination-inhibition antibodies in Sydney
Chuikova et al. The results of research of reactogenity and immunologic efficacy of hepatitis A and B with purified concentrated adsorbed liquid" HEP-A+ B-in-VAC" vaccine
Torre et al. Duration of immunity to hepatitis B vaccination in institutionalized mentally retarded patients
Karra et al. 64. DIAGNOSIS & MANAGEMENT OF HEPATITIS B
World Health Organization HEPATITIS: Acute viral hepatitis, 1985= HÉPATITE: Hépatite virale aiguë, 1985
JUNG Future strategies in hepatitis therapy: the immunological approach
Deinhardt Strategies in the Prevention of Infections by Oncogenic Viruses
Chalasani et al. Why do we need a newer generation of recombinant vaccines against hepatitis B?